AKTIENANLEIHE - BB BIOTECH N Share Price

Certificat

DE000VD2TYN8

Market Closed - Börse Stuttgart 07:36:51 17/05/2024 BST
94.44 EUR -0.19% Intraday chart for AKTIENANLEIHE - BB BIOTECH N
Current month+0.32%
1 month-2.07%
Date Price Change
17/05/24 94.44 -0.19%
16/05/24 94.62 +0.49%
15/05/24 94.16 +0.76%
14/05/24 93.45 +1.25%
13/05/24 92.3 -3.58%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 07:36 am

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying BB BIOTECH AG
IssuerLogo Issuer Vontobel Vontobel
WKN VD2TYN
ISINDE000VD2TYN8
Date issued 27/03/2024
Strike 45 CHF
Maturity 17/01/2025 (243 Days)
Parity 0.05 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 100.4
Lowest since issue 92.3

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
More about the company

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BB Biotech AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
41.7 CHF
Average target price
47.7 CHF
Spread / Average Target
+14.39%
Consensus